Daiichi Sankyo

Pfizer’s alliance with Sosei Heptares bears first fruit

Pfizer is just one of Sosei Heptares’ big pharma partners, and the company has also attracted sizeable collaborations with AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

Pivotal phase 2 data backs investment. AstraZeneca has the positive pivotal trial it needed to justify its big investment in Daiichi’s HER2-targeting antibody-drug conjugate DS-8201, a rival ... There are no anti-HER2 therapies currently approved for

Oncology drives AstraZeneca, Genzyme boosts Sanofi

AZ confirmed it will continue to drive oncology advancements, citing its recent partnership with Japan-based pharma group Daiichi Sankyo. ... Soriot adds: “The recently-announced collaboration with Daiichi Sankyo also broadened an exciting oncology

Second chance for AstraZeneca’s selumetinib with breakthrough designation

AstraZeneca has also just paid out a hefty $1.35bn upfront payment to become partners with Daiichi Sankyo on its late-stage antibody drug conjugate for HER2+ breast cancer.

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year. AstraZeneca has made a big bet on a HER2-targeted antibody-drug conjugate developed by Daiichi Sankyo as it tries to add another pillar to its ... Daiichi Sankyo has said that means its drug can carry a greater cytotoxic

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]